การกลายพันธุ์ของไวรัสตับอักเสบบี และความสำคัญทางคลินิก

Ganem, D., and Prince, A.M. 2004. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350: 1118-1129.

Kay, A., and Zoulim,F.2007. Hepatitis B virus genetic variability and evolution. Virus Res 127:164-176.

Blum, H.E. 1995. Variants of hepatitis B, Cand D viruses: molecular biology and clinical significance. Digestion 56:85-95.

Lewin, S.R., Ribeiro, R.M., Walters, T., Lau, G.K., Bowden, S., Locarnini, S., and Perelson, A.S. 2001. AnaIysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34: 1012-1020.

Locarnini, S., Shaw, T., Dean, J., Colledge, D., Thompson, A., Li, K., Lemon, S.M. Lau, G.G., and Beard, M.R. 2005. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J Clin Virol 32: 113-121.

Milich, D.R., Jones, J.E., Hughes, J.L., Price, J., Raney, A.K., and McLachlan, A. 1990. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 87:6599-6603.

Chotiyaputta, W., and Lok, A.S. 2009. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 6: 453-462.

Locamini, S., and Omata, M. 2006. Molecular virology of hepatitis B virus and the development of antiviral drug resistance. Liver Int 26 Suppl 2: 11-22.

Locarnini, S., McMillan, J., and Bartholomeusz, A. 2003. The hepatitis B virus and common mutants. Semin Liver Dis 23: 5-20.

Harrison, T.J. 2006. Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 26:87-96.

Tangkijvanich, P., Theamboonlers, A., Jantaradsamce, P., Hirsch, P., Mahachai, V., Suwangool, P., and Poovorawan, Y. 2000. Core promoter and precore mutants of hepatitis B virus: prevalence and clinical relevance in chronic hepatitis patients. Southeast Asian J Trop Med Public Health 31:627-635.

Theamboonlers, A., Tangkijvanich, P., Jantaradsamee, P., Hirsch, P., and Poovorawan, Y. 1999. Prevalence of core promotor and precore mutants of hepatitis B virus in thailand by RFLP and sequencing. Southeast Asian J Trop Med Public Health 30: 750-755.

Schaefer, S. 2005. Hepatitis B virus: significance of genotypes. J Viral Hepat 12: 111-124.

Tong, M.J., Blatt, L.M., Kao, J.H., Cheng, J.T., and Corey, W.G. 2007. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 27: 1356-1363.

Yang, H.I, Yeh,S.H Chen, P.J., lloeje, U.H.,Jen, C.L., Su, J., Wang, L.Y., Lu, S.N., You, S. Chen, D.S, et al. 2008. Associations between hepatititis virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100: 1134-1143.

Hunt, C.M., McGill, J.M., Allen, M.I., and Condreay, L.D. 2000. Climical relevance ofhepatitis B viral mutations. Hepatology 31: 1037-1044.

Malmassari, S.L., Deng, Q., Fontaine, H., Houitte, D., Rimlinger,F., Thiers, V, Maillere B., Pol, S., and Michel, M.L. 2007. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodomimant HBx-derived epitope. Hepatology 45: 1199-1209.

Hussain, S.P., Schwank, J., Staib, F., Wang, X.W., and Harris, C.C. 2007. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26: 2166-2176.

Liu, C.J., and Kao, J.H. 2008. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 13: 613-624.

Tangkijvanich, P., Sa-Nguanmoo, P., Mahachai, V., Theamboonlers, A., and Poovorawan, Y. 2010. A casecontrol study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int.

Benhenda, S., Cougot, D., Buendia, M.A., and Neuveut, C. 2009. Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv Cancer Res 103: 75-109.

Liu, C.J., and Kao, J.H. 2008. Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: story beyond A1762T/G1764A mutations. J Gastroenterol Hepatol 23: 347-350.

Huy, T.T., Ushijima, H., Win, K.M., Luengrojanakul, P., Shrestha, P.K., Zhong, Z.H., Smimov, A.V., Taltavull, T.C., Sata, T., and Abe, K. 2003. High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol 41: 5449-5455.

Tangkijvanich, P., Komolmit, Mahahachai, V., Sanguanmoo, P., Theamboonlers, A., and Poovorawan, Y. 2009. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic bepatitis B. J Clin Virol 46: 117-123.

Choi, M.S., Kim, D.Y., Lee, D.H., Lee, J.H., Koh, K.C, Paik, S.W., Rhee, J.C., and Yoo, B.C.2007 Clical significance of pre-S mutations in patients with genotype Chepatitis B virus infection. Viral Hepat 14: 161-168.

Chen, B.F., Liu, C.J., Jow, G.M., Chen, P.J., Kao, J.H., and Chen, D.S. 2006. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130: 1153-1168.

Wang, H.C., Huang, W., Lai, M.D., and Su, I.J. 2006. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 97:683-688.

Weber, B. 2005. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 32: 102-112.

Weber, B. 2005. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. Expert Rev Mol Diagn 5:75-91.

Suwannakarn, K., Tangkijvanich, P., Thawornsuk, N., Theamboonlers, A., Tharmaphornpilas, P., Yoocharoen, P., Chongsrisawat, V., and Poovorawan, Y.2007. Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatol Res.

Hsu, H.Y., Chang, M.H., Ni, Y.H., and Chen, H.L. 2004. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53: 1499-1503.

Badur, S., and Akgun, A. 2001. Diagnosis of hepatis B infections and monitoring of treatment. J Clin Virol 21: 229-237.

Kuhns, M.C., and Busch, M.P. 2006. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 10:77-91.

Fournier, C.,and Zoulim, F.2007. Antiviral therapy of chronic hepatitis B. prevention of drug resistance. Clin Liver Dis 11: 869-892, ix.

Locamini, S.A., and Yuen, L. 2010. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 15: 451-461.

Zhou, T, Saputelli, J, Aldrich, C.E., Deslauriers, Condreay, L.D, and Mason, W.S. 19999. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 43: 1947-1954.

Domingo, E. 2003. Quasispecies and the development of new antiviral strategies. Prog Drug Res 60: 133-158.

Chieochansin, T., Chutinimitkul, S., Payungpom, S., Theamboonlers, A., Tangkijvanich, P., Komolmit, P., and Poovorawan, Y. 2006. Rapid detection of lamivudine-resistant hepatitis B virus mutations by PCR-based methods. Tohoku J Exp Med 210: 67-78.

Seigneres, B., Pichoud, C., Martin, Furman, P, Trepo, C. and Zoulim, F.2002. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36: 710-722.

Colonno, R.J., Rose, R., Baldick, C.J., Levine, S., Pokornowski, K., Yu, C.F., Walsh, Fang, J., Hsu, M., Mazzucco, C., et al. 2006. Entecavir resistance is is in nucleoside naive patients with hepatitis B. Hepatology 44: 1656-1665.

Kamili, S., Sozzi, V., Thompson, G., Campbell, K., Walker, C.M., Locamini, S., and Krawczynski, K. 2009. Efficacy of hepatitis B vaccine against antiviral drugresistant hepatitis B virus mutants in the chimpanzee model. Hepatology 49: 1483-1491.